Cardiovascular diseases is the leading cause of mortality worldwide, underscoring the critical importance of preclinical drug screening and cardiac safety in cardiovascular therapeutics to mitigate the immense health and economic burdens. In vitro cardiomyocyte models have been utilized to develop drug evaluation biosensing platforms, leveraging their rhythmic mechanical contractions. However, conventional label-based methodologies pose challenges for long-term monitoring due to the drug adverse effect and phototoxicity, and video-based strategies necessitate high-resolution imaging but is constrained by low frame rates, while label-free biosensing platforms often require costly and time-consuming microfabrication techniques. Here, we introduce a mechanical contraction biosensing platform that incorporates a multi-channel size-regulable impedance sensor (SRIS) with a custom-developed detection system. The fabrication process of SRIS is straightforward and efficient, providing substantial benefits in terms of economic and temporal costs. Further, the SRIS platform strategically regulates three distinct electrode sizes, and the optimal driving frequency of each sensor is systematically determined. Through long-term dynamic cellular viability and contraction assessment, the cardiomyocyte-based contraction model is refined and prepared for drug evaluation. Three typical cardiac drugs are applied to modulate cardiomyocyte contraction function: a receptor agonist, an ion channel blocker, and a myosin inhibitor. The findings suggest that the SRIS platform proficiently captures the effects of both electrode size and drug concentration on cardiomyocyte contraction properties, thereby demonstrating its precise pharmacological assessment. This facilely fabricated, cost-effective, and size-regulable cardiomyocyte contraction biosensing platform holds significant potential for applications in cardiology and pharmacology research.
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号